TNBC Treatment Market to Reach USD 1.2B by 2032 at 6% CAGR; Roche, AstraZeneca Lead
Fact.MR today unveiled its latest report on the Triple Negative Breast Cancer Treatment Market, projecting steady yet impactful growth amid rising global breast cancer incidences and a push for innovative therapies targeting this aggressive subtype. Valued at USD 670.5 million in 2024, the global market is forecasted to expand at a compound annual growth rate (CAGR) of 4.6%, reaching USD 1.04...